Published in Ann Rheum Dis on October 01, 1992
Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother (2000) 1.03
Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res (2001) 1.01
Nitric oxide. Ann Rheum Dis (1996) 0.99
Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res (2008) 0.96
Computer based quantitative analysis of capillary abnormalities in systemic sclerosis and its relation to plasma concentration of von Willebrand factor. Ann Rheum Dis (1996) 0.83
The danger model approach to the pathogenesis of the rheumatic diseases. J Immunol Res (2015) 0.81
von Willebrand factor, exercise, and ischemia/reperfusion injury. Ann Rheum Dis (1993) 0.79
Combined genetic effects of EGLN1 and VWF modulate thrombotic outcome in hypoxia revealed by Ayurgenomics approach. J Transl Med (2015) 0.78
von Willebrand factor and vascular injury in rheumatoid arthritis. Ann Rheum Dis (1994) 0.75
A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A (1974) 9.94
Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem (1988) 2.80
Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol (1991) 2.59
Early joint lesions of rheumatoid arthritis; report of eight cases, with knee biopsies of lesions of less than one year's duration. AMA Arch Pathol (1955) 2.29
Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest (1989) 2.28
Oxygen tension in synovial fluids. Arthritis Rheum (1971) 2.14
Hypoxic-reperfusion injury in the inflamed human joint. Lancet (1989) 2.11
Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum (1971) 2.11
Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone. J Clin Invest (1988) 2.02
Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest (1987) 1.94
Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci (1982) 1.76
Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol Int (1987) 1.62
von Willebrand factor is an acute phase reactant in man. Thromb Res (1989) 1.48
Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis (1987) 1.43
Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest (1989) 1.36
Direct assessment of synovial blood flow and its relation to induced hydrostatic pressure changes. Ann Rheum Dis (1989) 1.31
Inhibition of human endothelial cell proliferation by gold compounds. J Clin Invest (1987) 1.22
Intraarticular pressure and the relationship between synovial perfusion and metabolic demand. J Rheumatol (1990) 1.17
Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J Rheumatol (1991) 1.14
A physiological approach to the assessment of disease activity in rheumatoid arthritis. J Clin Invest (1971) 1.10
Von Willebrand factor in the vessel wall mediates platelet adherence. Blood (1985) 1.09
Therapeutic value of graded aerobic exercise training in rheumatoid arthritis. Arthritis Rheum (1985) 1.08
Superoxide radical generation by inflamed human synovium after hypoxia. Lancet (1989) 1.08
Reciprocal relationship of synovial fluid volume and oxygen tension. Arthritis Rheum (1981) 1.05
Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. Growth Factors (1990) 1.03
Abnormal plasma levels of factor VIII/von Willebrand factor complex in myocardial infarction--expression of acute phase reaction or index of vascular endothelium damage? Thromb Haemost (1984) 1.02
Increased von Willebrand factor in diabetes mellitus. Metabolism (1979) 1.01
The effect of physical training on patients with rheumatoid arthritis: changes in disease activity, muscle strength and aerobic capacity. A clinically controlled minimized cross-over study. Clin Exp Rheumatol (1988) 1.00
Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med (1979) 0.99
Correlation between plasma levels of growth factors and von Willebrand factor. Thromb Res (1989) 0.97
Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity. J Appl Physiol (1985) (1986) 0.95
Arterial endothelial permeability and vascular disease. The "trap door" effect. Exp Mol Pathol (1973) 0.94
Influence of disodium aurothiomalate on the activities of xanthine dehydrogenase and xanthine oxidase in endothelial cells. Agents Actions Suppl (1991) 0.86
Phast assessment of vWf:Ag multimeric distribution. Thromb Res (1990) 0.83
von Willebrand factor release induced by endotoxin. J Lab Clin Med (1989) 0.81
Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med (1992) 5.97
Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J (1973) 4.13
Human parvovirus arthropathy. Lancet (1985) 3.76
Characteristics of socially isolated patients with coronary artery disease who are at elevated risk for mortality. Psychosom Med (2001) 3.38
Self-poisoning: management of patients in Nottingham, 1976. Br Med J (1978) 3.24
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Qualitative study of interpretation of reassurance among patients attending rheumatology clinics: "just a touch of arthritis, doctor?". BMJ (2000) 3.05
The Cook-Medley hostility scale: item content and ability to predict survival. Psychosom Med (1989) 2.90
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Why deny ACE inhibitors to patients with aortic stenosis? Lancet (1998) 2.62
Simulating sensory-motor incongruence in healthy volunteers: implications for a cortical model of pain. Rheumatology (Oxford) (2005) 2.52
Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett (1998) 2.49
Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis (1987) 2.48
The importance of iron in rheumatoid disease. Lancet (1981) 2.44
The patient is not a blank sheet: lay beliefs and their relevance to patient education. Br J Rheumatol (1989) 2.42
Continuing worldwide increase in tropospheric methane, 1978 to 1987. Science (1988) 2.30
A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum (1991) 2.18
Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut (1994) 2.10
Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum (1996) 2.07
Description of the analysis of a wide range of volatile organic compounds in whole air samples collected during PEM-tropics A and B. Anal Chem (2001) 2.07
Hostility, CHD incidence, and total mortality: a 25-year follow-up study of 255 physicians. Psychosom Med (1983) 2.05
Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem (2000) 1.93
Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology (1992) 1.92
Joint stiffness in a phantom limb: evidence of central nervous system involvement in rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.90
Organic aerosol formation downwind from the Deepwater Horizon oil spill. Science (2011) 1.89
Rabies in Alaska. Can J Comp Med Vet Sci (1949) 1.83
Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology (1985) 1.77
Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet (1987) 1.69
A neurogenic mechanism for symmetrical arthritis. Lancet (1989) 1.69
Stress in employed women: impact of marital status and children at home on neurohormone output and home strain. Psychosom Med (1997) 1.66
Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull (1995) 1.65
Hostility during late adolescence predicts coronary risk factors at mid-life. Am J Epidemiol (1992) 1.64
Inactivation of the elastase inhibitory activity of alpha 1 antitrypsin in fresh samples of synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis (1991) 1.61
Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol (1996) 1.61
Depressive symptoms and survival of patients with coronary artery disease. Psychosom Med (2001) 1.59
Von Willebrand factor--cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol (2000) 1.58
Extra-adrenal myelolipomas compared with extramedullary hematopoietic tumors: a case of presacral myelolipoma. Am J Surg Pathol (1982) 1.57
Neuroendocrine, cardiovascular, and emotional responses of hostile men: the role of interpersonal challenge. Psychosom Med (1998) 1.56
Type A behavior, hostility, and coronary atherosclerosis. Psychosom Med (1980) 1.55
Social support, type A behavior, and coronary artery disease. Psychosom Med (1987) 1.52
Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis (1983) 1.52
Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol (1998) 1.51
Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. J Clin Invest (1985) 1.51
Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience (1990) 1.49
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Protection against superoxide and hydrogen peroxide in synovial fluid from rheumatoid patients. Clin Sci (Lond) (1981) 1.48
The association between self-rated health and mortality in a well-characterized sample of coronary artery disease patients. Med Care (1999) 1.47
Exercise training in healthy type A middle-aged men: effects on behavioral and cardiovascular responses. Psychosom Med (1988) 1.45
Is chronic synovitis an example of reperfusion injury? Ann Rheum Dis (1986) 1.45
Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis (1993) 1.45
Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun (1998) 1.42
Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis (1985) 1.41
Photosynthetic control of atmospheric carbonyl sulfide during the growing season. Science (2008) 1.40
Oxygen free radicals, inflammation, and synovitis: and synovitis: the current status. Ann Rheum Dis (1989) 1.40
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut (1996) 1.39
Cortical origins of pathological pain. Lancet (2000) 1.39
Measuring outcome in rheumatoid arthritis--which measures are suitable for routine clinical use? Br J Rheumatol (1996) 1.39
A controlled pilot study of the utility of mirror visual feedback in the treatment of complex regional pain syndrome (type 1). Rheumatology (Oxford) (2003) 1.38
Mucosal reactive oxygen metabolite production in duodenal ulcer disease. Gut (1992) 1.36
Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. Psychosom Med (1982) 1.36
Hostility patterns and health implications: correlates of Cook-Medley Hostility Scale scores in a national survey. Health Psychol (1991) 1.35
Personality measures as predictors of smoking initiation and cessation in the UNC Alumni Heart Study. Health Psychol (1994) 1.33
Oxidants, inflammation, and anti-inflammatory drugs. FASEB J (1988) 1.32
Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-n.m.r. spectroscopy. Biochem J (1991) 1.32
Free radicals in inflammation: second messengers and mediators of tissue destruction. Br Med Bull (1993) 1.30
Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest (1989) 1.30
Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes. Proc Natl Acad Sci U S A (2007) 1.28
Neurogenic influences in arthritis. Ann Rheum Dis (1990) 1.23
Restless leg syndrome and rheumatoid arthritis. Br Med J (Clin Res Ed) (1986) 1.22
Klebsiella antibodies in ankylosing spondylitis and Proteus antibodies in rheumatoid arthritis. Br J Rheumatol (1988) 1.22
Xanthine oxidoreductase is present in human synovium. Ann Rheum Dis (1987) 1.21
Cerebral and ocular toxicity induced by desferrioxamine. Q J Med (1985) 1.21
Components of Type A, hostility, and anger-in: relationship to angiographic findings. Psychosom Med (1985) 1.20
The effect of synovial iron on the progression of rheumatoid disease. A histologic assessment of patients with early rheumatoid synovitis. Arthritis Rheum (1984) 1.20
Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochem Biophys Res Commun (1992) 1.19
Hypoxia and inflammatory synovitis: observations and speculation. Ann Rheum Dis (1991) 1.19
The experimental production of zinc deficiency in the rat. Br J Nutr (1970) 1.19
Human xanthine oxidase converts nitrite ions into nitric oxide (NO). Biochem Soc Trans (1997) 1.17
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (1985) 1.17
Assessment of iron stores in inflammation by assay of serum ferritin concentrations. Br Med J (Clin Res Ed) (1981) 1.16
Synovial fluid ferritin in rheumatoid arthritis. Br Med J (1980) 1.14
Forty years of monensin for the control of coccidiosis in poultry. Poult Sci (2010) 1.14
Social support and hostility as predictors of depressive symptoms in cardiac patients one month after hospitalization: a prospective study. Psychosom Med (1999) 1.14
Self-poisoning: psychiatric assessment by junior staff. Br Med J (1979) 1.13
Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis (1993) 1.12
Potent and selective hydroxynaphthoquinone inhibitors of mitochondrial electron transport in Eimeria tenella (Apicomplexa: Coccidia). Biochem Pharmacol (1984) 1.12
Reactive oxygen species and iron--a dangerous partnership in inflammation. Int J Biochem Cell Biol (1995) 1.12
The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J (1985) 1.11
Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett (1992) 1.10
Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis (2003) 1.09
Situational determinants of cardiovascular and emotional reactivity in high and low hostile men. Psychosom Med (1989) 1.08
Caecal deformity in the fowl. Vet Rec (1991) 1.08
Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis (1997) 1.08
Breath sulfides and pulmonary function in cystic fibrosis. Proc Natl Acad Sci U S A (2005) 1.08